+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gastrointestinal Stromal Tumor Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5933881
The gastrointestinal stromal tumor market size has grown strongly in recent years. It will grow from $1.18 billion in 2023 to $1.28 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth observed in the historical period can be attributed to increased awareness and early diagnosis, the emergence of targeted therapies, enhanced surgical techniques, the development of personalized medicine, and improvements in supportive care.

The gastrointestinal stromal tumor market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The anticipated growth in the forecast period can be attributed to continued research and drug development, a rise in patient-centric healthcare, the integration of precision medicine into clinical practice, increasing access to targeted therapies, and expanding genomic profiling capabilities. Key trends expected in the forecast period include growing collaboration in research and development, advancements in diagnostic technologies, collaborative research and clinical trials, increased focus on early detection and diagnosis, and exploration of combination therapies.

The anticipated increase in stomach cancer cases is poised to drive the growth of the gastrointestinal stromal tumor market. Stomach cancer, characterized by the uncontrolled growth of malignant cells in the stomach lining, is distinct from gastrointestinal stromal tumors (GISTs), although GISTs can occur in the stomach. Interestingly, individuals with GISTs who develop two separate tumors that merge into one have an elevated risk of additional cancers, including small bowel adenocarcinoma. For example, Cancer Research UK projects a 12% decline in stomach cancer incidence in the UK between 2023-2025 and 2038-2040, reaching an average of 8 cases per 100,000 people annually. Thus, the increasing occurrence of stomach cancer is a key driver propelling the gastrointestinal stromal tumor market.

The growing demand for precision medicine is expected to fuel the expansion of the gastrointestinal stromal tumor market. Precision medicine, tailored to individual patient characteristics such as genetics and lifestyle, is a targeted approach to medical treatment. In the case of gastrointestinal stromal tumors, precision medicine involves molecular profiling to identify specific mutations, guiding therapies such as imatinib. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research approved 37 new molecular entities, with 34% classified as personalized medicines. This rise in precision medicine adoption contributes to the growth of the gastrointestinal stromal tumor market.

The limitation of health awareness and literacy is anticipated to hinder the growth of the gastrointestinal stromal tumors (GIST) market. Limited awareness of safety regulations and guidelines can lead to accidents and injuries when handling drums, similar to the constraints faced in gastrointestinal stromal tumor management due to a lack of awareness about chronic disease treatment. Enhancing awareness within healthcare and research communities and among the general public is crucial to addressing cancer as a significant health issue. Therefore, the lack of health awareness and literacy significantly constrains the growth potential of the gastrointestinal stromal tumors market, hindering improvements in patient outcomes.

Major companies in the gastrointestinal stromal tumor market are introducing innovative drugs such as QINLOCK (Ripretinib) to cater to larger customer bases, boost sales, and increase revenue. QINLOCK (Ripretinib) is a prescription medicine approved for the treatment of advanced gastrointestinal stromal tumor (GIST). For instance, Zai Lab Ltd, a China-based biotechnology company, announced the approval of QINLOCK (Ripretinib) by the National Medical Products Administration (NMPA) of China in March 2021. This drug is prescribed for the treatment of advanced GIST in adult patients who have previously undergone treatment with three or more kinase inhibitors, including imatinib.

In June 2022, Immatics N.V., a Germany-based biotechnology company, formed a partnership with Bristol Myers Squibb to develop gamma delta allogeneic cell therapy programs. This collaboration aims to create advanced cancer immunotherapies with the potential to enhance the treatment of various cancers, including gastrointestinal stromal tumors (GISTs). Bristol Myers Squibb, a US-based pharmaceutical company, is actively involved in developing treatments related to GISTs.

Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.

North America was the largest region in the gastrointestinal stromal tumor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the gastrointestinal stromal tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastrointestinal stromal tumor market includes revenues earned by entities by providing services such as diagnostic services, pathology services, pathology services, and pathology services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal stromal tumor market also includes sales of targeted therapy, chemotherapy, radiation therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The main treatment modalities for gastrointestinal stromal tumors include chemotherapy, targeted therapy, and others. Chemotherapy is a medical treatment that utilizes potent drugs to target and eliminate rapidly dividing cells in the body, including cancer cells. It is prescribed for various indications such as those affecting the stomach, small intestine, and other parts of the GI tract. Different end-users, including hospitals, clinics, specialized cancer treatment centers, and others, may administer chemotherapy as part of the treatment regimen.

The gastrointestinal stromal tumor market research report is one of a series of new reports that provides gastrointestinal stromal tumor market statistics, including gastrointestinal stromal tumor industry global market size, regional shares, competitors with a gastrointestinal stromal tumor market share, detailed gastrointestinal stromal tumor market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal stromal tumor industry. This gastrointestinal stromal tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Gastrointestinal Stromal Tumor Market Characteristics3. Gastrointestinal Stromal Tumor Market Trends and Strategies
4. Gastrointestinal Stromal Tumor Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Gastrointestinal Stromal Tumor Market Size and Growth
5.1. Global Gastrointestinal Stromal Tumor Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Gastrointestinal Stromal Tumor Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Gastrointestinal Stromal Tumor Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Gastrointestinal Stromal Tumor Market Segmentation
6.1. Global Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Targeted Therapy
  • Other Treatment Types
6.2. Global Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Stomach
  • Small Intestine
  • Others Indications
6.3. Global Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Specialized Cancer Treatment Centers
  • Other End-Users
7. Gastrointestinal Stromal Tumor Market Regional and Country Analysis
7.1. Global Gastrointestinal Stromal Tumor Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Gastrointestinal Stromal Tumor Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Gastrointestinal Stromal Tumor Market
8.1. Asia-Pacific Gastrointestinal Stromal Tumor Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Gastrointestinal Stromal Tumor Market
9.1. China Gastrointestinal Stromal Tumor Market Overview
9.2. China Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Gastrointestinal Stromal Tumor Market
10.1. India Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Gastrointestinal Stromal Tumor Market
11.1. Japan Gastrointestinal Stromal Tumor Market Overview
11.2. Japan Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Gastrointestinal Stromal Tumor Market
12.1. Australia Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Gastrointestinal Stromal Tumor Market
13.1. Indonesia Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Gastrointestinal Stromal Tumor Market
14.1. South Korea Gastrointestinal Stromal Tumor Market Overview
14.2. South Korea Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Gastrointestinal Stromal Tumor Market
15.1. Western Europe Gastrointestinal Stromal Tumor Market Overview
15.2. Western Europe Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Gastrointestinal Stromal Tumor Market
16.1. UK Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Gastrointestinal Stromal Tumor Market
17.1. Germany Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Gastrointestinal Stromal Tumor Market
18.5. France Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Gastrointestinal Stromal Tumor Market
19.9. Italy Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Gastrointestinal Stromal Tumor Market
20.13. Spain Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Gastrointestinal Stromal Tumor Market
21.1. Eastern Europe Gastrointestinal Stromal Tumor Market Overview
21.2. Eastern Europe Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Gastrointestinal Stromal Tumor Market
22.1. Russia Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Gastrointestinal Stromal Tumor Market
23.1. North America Gastrointestinal Stromal Tumor Market Overview
23.2. North America Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Gastrointestinal Stromal Tumor Market
24.1. USA Gastrointestinal Stromal Tumor Market Overview
24.2. USA Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Gastrointestinal Stromal Tumor Market
25.1. Canada Gastrointestinal Stromal Tumor Market Overview
25.2. Canada Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Gastrointestinal Stromal Tumor Market
26.1. South America Gastrointestinal Stromal Tumor Market Overview
26.2. South America Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Gastrointestinal Stromal Tumor Market
27.1. Brazil Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Gastrointestinal Stromal Tumor Market
28.1. Middle East Gastrointestinal Stromal Tumor Market Overview
28.2. Middle East Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Gastrointestinal Stromal Tumor Market
29.1. Africa Gastrointestinal Stromal Tumor Market Overview
29.2. Africa Gastrointestinal Stromal Tumor Market, Segmentation by Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Gastrointestinal Stromal Tumor Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Gastrointestinal Stromal Tumor Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Gastrointestinal Stromal Tumor Market Competitive Landscape and Company Profiles
30.1. Gastrointestinal Stromal Tumor Market Competitive Landscape
30.2. Gastrointestinal Stromal Tumor Market Company Profiles
30.2.1. Pfizer Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. F. Hoffmann-La Roche AG
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Bayer AG
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Novartis AG
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Merck & Co. Inc.
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Gastrointestinal Stromal Tumor Market Other Major and Innovative Companies
31.1. GlaxoSmithKline plc
31.2. Bristol-Myers Squibb Company
31.3. Sanofi S.a.
31.4. AstraZeneca plc
31.5. Eli Lilly and Company
31.6. Daiichi Sankyo Co. Ltd.
31.7. Eisai Co. Ltd.
31.8. Sun Pharmaceutical Industries Limited
31.9. Jiangsu Hengrui Medicine Co. Ltd.
31.10. Exelixis Inc.
31.11. NATCO Pharma Ltd.
31.12. Blueprint Medicines Corporation
31.13. Array BioPharma Inc.
31.14. Deciphera Pharmaceuticals Inc.
31.15. Ono Pharmaceutical Co. Ltd.
32. Global Gastrointestinal Stromal Tumor Market Competitive Benchmarking33. Global Gastrointestinal Stromal Tumor Market Competitive Dashboard34. Key Mergers and Acquisitions in the Gastrointestinal Stromal Tumor Market
35. Gastrointestinal Stromal Tumor Market Future Outlook and Potential Analysis
35.1 Gastrointestinal Stromal Tumor Market in 2028 - Countries Offering Most New Opportunities
35.2 Gastrointestinal Stromal Tumor Market in 2028 - Segments Offering Most New Opportunities
35.3 Gastrointestinal Stromal Tumor Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Gastrointestinal Stromal Tumor Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastrointestinal stromal tumor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for gastrointestinal stromal tumor? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Scope

Markets Covered:
1) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types
2) By Indication: Stomach; Small Intestine; Others Indications
3) By End-User: Hospitals; Clinics; Specialized Cancer Treatment Centers; Other End-Users

Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bayer AG; Novartis AG; Merck & Co. Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Methodology

Loading
LOADING...